Founded in 2010, Cerebral Therapeutics focuses on providing alternative treatments for patients with chronic neurological diseases who do not respond to conventional medications. Their therapies use reformulated off-patent drugs delivered directly to the brain's ventricles, bypassing the blood-brain barrier. This approach aims to improve treatment outcomes and minimize systemic medication side effects. The company utilizes a proprietary implanted infusion system to deliver continuous doses of their drug, CT-010, intracerebroventricularly (ICV). Cerebral Therapeutics aims to increase brain exposure, maximize efficacy, reduce systemic drug exposure, and enhance therapy adherence.